4.5 Interaction with other medicinal products and other forms of interaction  
 Based upon in vitro  data, migalastat is not an inducer of CYP1A2 , 2B6 , or 3A4.  Furthermore, migalastat is not an inhibitor or a substrate of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 
3A4/5 . Migalastat is not a substrate for MDR1 or BCRP, nor is it an inhibitor of BCRP, MDR1, or BSEP human efflux transporters. In addition, migalastat is not a substrate for MATE1, MATE2 -K, OAT1, OAT3, or OCT2, nor is it an inhibitor of OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2 -K human uptake transporte rs. 
 Effect of other drugs on migalastat  
 Co-administration of migalastat with caffeine decrease s migalastat systemic exposure ( AUC and Cmax) which may reduce Galafold efficacy (see section 5.2). A void co -administration of Galafold with caffeine at least 2  hours before and 2  hours after taking Galafold (see section 4.2) .  
 
 
